Evidence map›Paper›PMID 27174710›Full record

ArticleScientific reports2016

Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal.

Tao Wang, Lei Xia, Sicong Ma, Xingxing Qi, Qigen Li, Yun Xia, Xiaoyin Tang, Dan Cui, Zhi Wang, Jiachang Chi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tao WangDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Lei XiaDepartment of Hepatic surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Sicong MaDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Xingxing QiDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Qigen LiDepartment of Hepatic surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Yun XiaDepartment of Hepatic surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Xiaoyin TangDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Dan CuiDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Zhi WangDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Jiachang ChiDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Ping LiDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Yu-Xiong FengDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Qiang XiaDepartment of Hepatic surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Bo ZhaiDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC, 200127.
Renji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem-like cells (CSCs) play a key role in maintaining the aggressiveness of hepatocellular carcinoma (HCC), but the cell-biological regulation of CSCs is unclear. In the study, we report that thyroid hormone (TH) promotes cell self-renewal in HCC cells. TH also increases the percentage of CD90 + HCC cells and promotes drug resistance of HCC cells. By analyzing primary human HCC samples, we found that TRα transcript level is significantly elevated in primary liver cancer and portal vein metastatic tumor, compared to that of adjacent normal liver tissue. Knocking down TRα not only inhibits HCC self-renewal in vitro but also suppresses HCC tumor growth in vivo. Interestingly, treatment of TH leads to activation of NF-κB, which is required for the function of TH on inducing HCC cell self-renewal. We also found TRα and p65 cooperatively drive the expression of BMI1 by co-binding to the promoter region of BMI1 gene. In summary, our study uncovers a novel function of TH signaling in regulating the CSCs of HCC, and these findings might be useful for developing novel therapies by targeting TH function in HCC cells.

Indexed as

Carcinoma, HepatocellularCell Self RenewalHumansLiver NeoplasmsNeoplastic Stem CellsNF-kappa BSignal TransductionThyroid Hormone Receptors alphaThyroid HormonesTumor Cells, CulturedNF-kappa BThyroid Hormone Receptors alphaThyroid Hormones

Identifiers

PMID27174710
PMCPMC4865859
OpenAlexW2380065327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.